Post-Covid related disruptions in Q1FY21, Bal Pharma witnessed robust growth in Q1FY22. The company has delivered an all-round performance with Revenue registering a growth of 36% yoy to Rs71cr in Q1FY22 compared to Rs52.3cr in Q1FY21.
EBITDA grew by 46% yoy to Rs7.6cr in Q1FY22 compared to Rs5.2cr in Q1FY21. EBITDA margins too witnessed an expansion of 70bps yoy to 10.7% from 10% In Q1FY21. Resolution of logistics and supply chain related issue for Raw material led to overall improvement in EBITDA margins.
Profit After Tax (PAT) grew by 5x to Rs1.65cr in Q1FY22 compared to Rs0.28cr in Q1FY21. All supply side logistics bottlenecks have been gradually fading away, along with strong export demand has led to sharp recovery in company’s earnings. Better operating leverage and lower overheads led to overall increase in PAT.
Bal Pharma Ltd ended at Rs95.90 per piece up by Rs2.15 or 2.29% from its previous closing of Rs93.75 per piece on the BSE.
“Strong contribution from API business led to Revenue growth of 36% yoy. Such overall revenue growth was on account of non-covid therapeutic segments and robust demand both in the domestic and International markets. API segment revenue reported an increase of 78% yoy to Rs44.86cr in Q1FY22. Share of API in total revenue increase to 64% in Q1FY22 from 49% in Q1FY21. Formulations segment remained flat on yoy Basis at Rs25.7cr,” company said.